Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Res. 2017 Feb 27;15(7):905–914. doi: 10.1158/1541-7786.MCR-16-0369

Figure 5. USP18 expression is higher in Kras mutant murine lung cancers and USP18 loss reduces tumorigenicity of Kras-driven murine lung cancers.

Figure 5

(A) USP18 expression is significantly (P < 0.001) elevated in Kras-driven murine lung cancers relative to cyclin E-driven murine lung cancers. Representative USP18 immunostaining of normal versus malignant lung tissues harvested independently from cyclin E-transgenic mice (n = 3) and KrasLA2/+ mice (n = 3). All magnifications are 20X. Average USP18 immunostaining in malignant lung was determined. (B) Loss of Usp18 significantly (P < 0.05) decreased the number of Kras-driven murine lung cancers. Average lung tumor numbers of KrasLA2/+Usp18+/+ (n = 25), KrasLA2/+Usp18+/− (n = 19) and KrasLA2/+Usp18−/− (n = 20) mice were determined for each respective group. (C) Loss of Usp18 significantly (P < 0.01) decreased cyclin D1 expression in Kras-driven murine lung cancers. Representative cyclin D1 immunostaining of malignant lung with low versus high cyclin D1 expression are shown. All magnifications are 40X. Average cyclin D1 immunostaining of lung cancer was determined in KrasLA2/+Usp18+/+ (n = 16) and KrasLA2/+Usp18−/− (n = 15) mice, respectively.